Indonesia Energy Corporation Limited vs Eli Lilly And Co — how do they compare? Indonesia Energy Corporation Limited trades at $2.91 (market cap $44.93M), while Eli Lilly And Co trades at $1,215.39 (market cap $1.10T). The key difference: Eli Lilly And Co is far larger — about 24482.5× Indonesia Energy Corporation Limited's market cap, and Eli Lilly And Co pays a 0.56% dividend while Indonesia Energy Corporation Limited pays none. Which is the better fit depends on your goals.
| INDO | LLY | |
|---|---|---|
Market Cap | $44.93M | $1.10T |
Sector | Energy | Health |
52-Week High | $6.74 | $1.24K |
52-Week Low | $2.49 | $639.43 |
Enterprise Value | $40.30M | $1.14T |
Dividend Yield | — | 0.56% |
Signals from Pluang's Aura AI — not financial advice
INDO trades at $2.80 with a slight 0.72% daily gain. The technical picture is bearish with moving averages signaling caution, while fundamentals show significant challenges with negative profit margins (-253.4%) and weak revenue of $2M in 2025. Recent news highlights operational progress with drilling commencement at the K-29 well. Analyst consensus remains unanimously bullish with 3 buy ratings.
The outlook is speculative given deep losses, but drilling success could drive upside. Key risks include execution in exploration, sustained negative cash flow, and oil price volatility. The stock presents high-risk potential for investors betting on operational turnaround versus current financial distress.
Eli Lilly (LLY) trades at $1,185.71, down 0.59% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q2 2026 revenue growth of 48% to $23 billion, beating estimates, driven by demand for Mounjaro and Zepbound. Valuation ratios like P/E of 39.8 and P/S of 13.34 reflect high growth expectations, while profitability remains robust with a net income margin of 33.53%.
Outlook is positive due to pipeline advancements like retatrutide and raised 2026 guidance, but risks include competitive pressures and regulatory scrutiny. Analysts are bullish with a consensus price target of $1,380, citing sustained double-digit growth and market leadership in weight-loss drugs as key drivers for upside.
Trailing returns across standard periods
Latest headlines on both assets
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →